On March 6, 2024 Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its unique Mimicry platform, reported that data on its novel OncoMimics approach to cancer immunotherapy will be presented in a poster at the upcoming American Association of Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, taking place April 5-10 in San Diego, California (Press release, Enterome, MAR 6, 2024, View Source [SID1234640853]). The poster will be presented by Dr. Vincent Panneton, Postdoctoral Associate in Pharmacology at the Ludwig Collaborative Laboratory led by Dr. Taha Merghoub and Dr. Jedd Wolchok at Weill Cornell Medicine.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Research conducted by Weill Cornell Medicine and Enterome shows that in animal models microbiome-derived antigenic peptides (OncoMimics peptides), selected for their mimicry of tumor-associated antigens (TAAs) and neoantigens, effectively trigger cytotoxic T-cell immune responses. Through tumor challenge experiments with OncoMimics and checkpoint inhibitors, the researchers have also identified key parameters that enable them to predict the cross-reactive potential of OncoMimics peptides and facilitate the development of novel cancer immunotherapies.
"We are pleased to announce the presentation of these promising preclinical data which provide novel insights into the design of OncoMimics peptides for both neoantigens and tumor-associated antigens. These results serve as an early validation of our approach to novel cancer immunotherapies," said Laurent Chêne, Head of Drug Discovery at Enterome.
Poster presentation details – Abstract 4090
Title: "Gut Microbiota Mimics as a Source of Cross-Reactive Tumor Rejection Antigens"
Presenting Author: Vincent Panneton, Ph.D., Postdoctoral Associate Weill Cornell Medicine
Session date: Tuesday Apr 9th, 2024 9 AM – 12:30
Location : Poster section 5, board number 1
The abstract will be published in an online supplement to Cancer Research, the official journal of the American Association for Cancer Research (AACR) (Free AACR Whitepaper), on March 22nd, and the poster will be available on Enterome’s website after the AACR (Free AACR Whitepaper) Meeting.
About OncoMimics
OncoMimics immunotherapies are designed to activate pre-existing effector memory T cells that target bacterial (non-self) peptides, which are strongly cross-reactive against selected Tumor-Associated Antigens (TAAs), or B cell markers expressed on tumoral cells, resulting in a rapid, targeted cytotoxic response against cancer.